These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 3728307)

  • 1. Effects of probucol on xanthomata regression in familial hypercholesterolemia.
    Yamamoto A; Matsuzawa Y; Yokoyama S; Funahashi T; Yamamura T; Kishino B
    Am J Cardiol; 1986 Jun; 57(16):29H-35H. PubMed ID: 3728307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of probucol and cholestyramine combination therapy in severe familial hypercholesterolaemia.
    Jackson JM; Lee HA
    Atherosclerosis; 1984; 51(2-3):189-97. PubMed ID: 6743378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of probucol on homozygous cases of familial hypercholesterolemia.
    Yamamoto A; Matsuzawa Y; Kishino B; Hayashi R; Hirobe K; Kikkawa T
    Atherosclerosis; 1983 Aug; 48(2):157-66. PubMed ID: 6615580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
    Yamamoto A; Yamamura T; Yokoyama S; Sudo H; Matsuzawa Y
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):493-7. PubMed ID: 6500769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
    Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI
    Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
    N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
    Inazu A; Koizumi J; Kajinami K; Kiyohar T; Chichibu K; Mabuchi H
    Atherosclerosis; 1999 Aug; 145(2):405-13. PubMed ID: 10488970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
    Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
    Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.
    Kajinami K; Nishitsuji M; Takeda Y; Shimizu M; Koizumi J; Mabuchi H
    Atherosclerosis; 1996 Feb; 120(1-2):181-7. PubMed ID: 8645359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
    Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
    Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
    Mabuchi H; Koizumi J; Kajinami K
    Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein fractions and receptors: a role for probucol?
    Bilheimer DW
    Am J Cardiol; 1986 Jun; 57(16):7H-15H. PubMed ID: 3637051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease.
    Kuo PT; Wilson AC; Kostis JB; Moreyra AE
    Am J Cardiol; 1986 Jun; 57(16):43H-48H. PubMed ID: 3524177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of hyperlipidemia and the role of probucol.
    Davignon J
    Am J Cardiol; 1986 Jun; 57(16):22H-28H. PubMed ID: 3460320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
    Durrington PN; Miller JP
    Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current pharmacologic treatment of elevated serum cholesterol.
    Tikkanen MJ; Nikkilä EA
    Circulation; 1987 Sep; 76(3):529-33. PubMed ID: 3476221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of intensive long-term treatment of familial hypercholesterolemia.
    Retterstøl K; Stugaard M; Gørbitz C; Ose L
    Am J Cardiol; 1996 Dec; 78(12):1369-74. PubMed ID: 8970408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with simvastatin compared with cholestyramine.
    Erkelens DW; Baggen MG; Van Doormaal JJ; Kettner M; Koningsberger JC; Mol MJ
    Drugs; 1988; 36 Suppl 3():87-92. PubMed ID: 3254824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.